14.16
前日終値:
$14.07
開ける:
$14.11
24時間の取引高:
1.13M
Relative Volume:
1.00
時価総額:
$11.82B
収益:
$3.85B
当期純損益:
$667.93M
株価収益率:
21.55
EPS:
0.657
ネットキャッシュフロー:
$142.30M
1週間 パフォーマンス:
-0.42%
1か月 パフォーマンス:
-0.21%
6か月 パフォーマンス:
+6.95%
1年 パフォーマンス:
-11.02%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
RDY を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
RDY
Dr Reddys Laboratories Ltd Adr
|
14.16 | 11.71B | 3.85B | 667.93M | 142.30M | 0.657 |
![]()
ZTS
Zoetis Inc
|
146.42 | 64.92B | 9.39B | 2.62B | 2.22B | 5.8121 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.60 | 45.60B | 29.96B | 957.25M | 4.77B | 0.2956 |
![]()
HLN
Haleon Plc Adr
|
8.95 | 39.54B | 14.26B | 1.98B | 2.47B | 0.4327 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.01 | 23.00B | 16.70B | -157.13M | 1.19B | -0.155 |
![]()
UTHR
United Therapeutics Corp
|
453.07 | 20.06B | 2.99B | 1.21B | 1.13B | 25.06 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-05 | アップグレード | HSBC Securities | Hold → Buy |
2024-12-19 | ダウングレード | Nomura | Buy → Neutral |
2024-01-11 | ダウングレード | Jefferies | Buy → Underperform |
2023-08-29 | ダウングレード | HSBC Securities | Buy → Hold |
2023-05-18 | ダウングレード | Bernstein | Outperform → Mkt Perform |
2023-03-17 | アップグレード | BofA Securities | Neutral → Buy |
2023-01-30 | 開始されました | JP Morgan | Underweight |
2022-11-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
2022-01-03 | 再開されました | BofA Securities | Neutral |
2021-07-27 | ダウングレード | Credit Suisse | Outperform → Neutral |
2021-02-02 | アップグレード | Barclays | Equal Weight → Overweight |
2020-09-18 | アップグレード | BofA Securities | Neutral → Buy |
2020-09-18 | アップグレード | Investec | Sell → Hold |
2020-01-28 | ダウングレード | CLSA | Buy → Outperform |
2020-01-27 | ダウングレード | CLSA | Buy → Outperform |
2020-01-09 | アップグレード | Citigroup | Sell → Buy |
2019-11-04 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-09-04 | アップグレード | Credit Suisse | Underperform → Outperform |
2019-07-01 | アップグレード | Macquarie | Neutral → Outperform |
2019-06-20 | 開始されました | Deutsche Bank | Hold |
2019-06-11 | 開始されました | Barclays | Equal Weight |
2019-05-20 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2019-02-19 | アップグレード | CLSA | Outperform → Buy |
2019-01-17 | ダウングレード | Citigroup | Neutral → Sell |
2017-09-21 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-08-31 | アップグレード | CLSA | Underperform → Outperform |
2017-07-28 | ダウングレード | CLSA | Underperform → Sell |
2016-07-27 | ダウングレード | HSBC Securities | Hold → Reduce |
2016-07-27 | ダウングレード | Jefferies | Hold → Underperform |
2016-02-10 | アップグレード | Credit Agricole | Underperform → Buy |
2015-11-10 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Dr Reddys Laboratories Ltd Adr (RDY) 最新ニュース
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040 - GlobeNewswire Inc.
Asian ADRs Rise As Regional Firms Show Mixed Performance - Finimize
LLY Stock Quote Price and Forecast - CNN
Dr Reddys Share Price Update: Company Reports Negative Monthly Returns - Meyka
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
NVO Stock Quote Price and Forecast - CNN
Asian ADRs In The US Start The Week On A High Note - Finimize
Bizarre Stock Volatility? How Is H1B News Affecting Infosys & Wipro Share Prices On Saturday? - Free Press Journal
Asian ADR Index Edges Up As LG Display Leads - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares Under Employee Stock Option Scheme - The Globe and Mail
Dr Reddy's shares fall as USFDA flags Hyderabad plant with 5 observations - Business Standard
Asian ADRs Gain As Investors Show Renewed Interest - Finimize
Asian Equities In The US Logged Broad Gains This Session - Finimize
Mixed Performance For Asian Stocks Traded In The US - Finimize
Dr. Reddy’s Laboratories Allots Equity Shares to Employees - TipRanks
Invesco Ltd. Has $8.12 Million Stake in ATRenew Inc. Sponsored ADR $RERE - Defense World
Validea's Top Health Care Stocks Based On Peter Lynch8/25/2025 - Nasdaq
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - Barchart.com
National Bank of Canada FI Boosts Stock Position in Dr. Reddy's Laboratories Ltd $RDY - MarketBeat
Asian ADRs Trade Lower As S&P Asia 50 Index Drops - Finimize
Asian Tech Names Lift US-Traded Stocks To A Small Gain - Finimize
Dr. Reddy’s Subsidiary Imperial Dissolved Following NCLT Approval - TipRanks
(PDF) ADRs and underlying stock returns: empirical evidence from India - researchgate.net
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 50% Tariff On India - MSN
Asian Stocks In The US See Mixed Moves Across Sectors - Finimize
Trump hikes tariffs on India by additional 25% citing Russian oil trade; iShares India ETF, ADRs react - Moneycontrol
Asian ADRs Fall As Winners And Losers Stand Out - Finimize
Dr Reddys Laboratories Faces Continued Stock Decline Amid Broader Market Challenges - Markets Mojo
Asian ADRs Falter On US Markets As Fintechs Slide - Finimize
Trump’s Tariffs on India highlights: Sensex falls 800 points, Trump launches fresh attack on India for Russia ties - Mint
Trump Tariff Impact: Infosys, Wipro, HDFC Bank, Other ADR Shares Drop After US Levies 25% Tariff On India - MSN
Dr Reddys Laboratories Ltd Adr (RDY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):